Deprescribing Fall Risk–Increasing Drugs in Older Adults: Implementation Challenges and a Conceptual Framework from the DeFRID Trial and Global Evidence

Abstract Background Deprescribing fall risk–increasing drugs (FRIDs) is essential for reducing polypharmacy and falls in older adults, yet randomized controlled trials (RCTs) face unique implementation challenges. The DeFRID study is an ongoing multi-center RCT evaluating an ARMOR-based deprescribing intervention versus usual care in adults aged ≥60 years prescribed FRIDs. The objectives of this review are threefold: (1) to describe practical challenges encountered during a multi-center deprescribing RCT in India; (2) to propose a conceptual framework for categorizing these barriers; and (3) to contextualize DeFRID's experience within the broader deprescribing research landscape. Methods We conducted a narrative review with systematic scoping elements, synthesizing global RCT evidence from PubMed, OpenAlex, and Google Scholar (inception–December 2025) with DeFRID process evaluation data. DeFRID barriers and facilitators were identified via mixed-methods (clinician KAP questionnaire and qualitative interviews), team meetings, retention logs, and Phase II RCT implementation data, thematically categorized, then compared with global RCT challenges. Results DeFRID implementation revealed four challenge categories: ethical–clinical difficulties establishing equipoise for FRID withdrawal; operational barriers to recruitment and retention; methodological complexities in fall outcome ascertainment; and context-specific constraints unique to the Indian LMIC setting—limited deprescribing guidelines, polypharmacy normalization, fragmented care coordination, and hierarchical decision-making. Global RCTs revealed substantial implementation challenges: low clinician adherence, short follow-up periods, restrictive eligibility excluding frail or cognitively impaired older adults, and resource-intensive interventions limiting scalability. Conclusions Deprescribing FRIDs in older adults is impeded by ethical, operational, methodological, and provider-patient challenges, necessitating multilevel strategies integrating training, shared decision-making, context-specific guidelines, and stakeholder engagement for scalable implementation.

Authors

Institutions

Publication Details

Journal
The Journals of Gerontology Series A
Published
2026-10-08
DOI
https://doi.org/10.1093/gerona/glag248
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deprescribing Fall Risk–Increasing Drugs in Older Adults: Implementation Challenges and a Conceptual Framework from the DeFRID Trial and Global Evidence

Venugopalan Gunasekaran, Gerard Marshall Raj, Sandhiya Selvarajan, Gomathi Ramaswamy et al.
The Journals of Gerontology Series A
Pharmaceutical Practices and Patient Outcomes
article

Deprescribing Fall Risk–Increasing Drugs in Older Adults: Implementation Challenges and a Conceptual Framework from the DeFRID Trial and Global Evidence

Venugopalan Gunasekaran, Gerard Marshall Raj, Sandhiya Selvarajan, Gomathi Ramaswamy, Sakthivadivel Varatharajan, Rekha Priyadarshini, Veena Nayak, Tanu Anand, Sowparnika Treasa Sabu, Jerin Jose Cherian, Raghavendra A. Rao, Madhavi Eerike, Mukhyaprana M. Prabhu, Vassiliki Karra, Rijesh Potangadi, Priyadharsini Rajendran, Paul Mathai, Lokesh Kumar Sharma, Surendran Padinchara Kunhipilakkandiy, Selvaraj Jayachandran, Shivanand Kattimani, Narayanan Puthiya Veettil, Anu Chandran
article en

Abstract

Abstract Background Deprescribing fall risk–increasing drugs (FRIDs) is essential for reducing polypharmacy and falls in older adults, yet randomized controlled trials (RCTs) face unique implementation challenges. The DeFRID study is an ongoing multi-center RCT evaluating an ARMOR-based deprescribing intervention versus usual care in adults aged ≥60 years prescribed FRIDs. The objectives of this review are threefold: (1) to describe practical challenges encountered during a multi-center deprescribing RCT in India; (2) to propose a conceptual framework for categorizing these barriers; and (3) to contextualize DeFRID's experience within the broader deprescribing research landscape. Methods We conducted a narrative review with systematic scoping elements, synthesizing global RCT evidence from PubMed, OpenAlex, and Google Scholar (inception–December 2025) with DeFRID process evaluation data. DeFRID barriers and facilitators were identified via mixed-methods (clinician KAP questionnaire and qualitative interviews), team meetings, retention logs, and Phase II RCT implementation data, thematically categorized, then compared with global RCT challenges. Results DeFRID implementation revealed four challenge categories: ethical–clinical difficulties establishing equipoise for FRID withdrawal; operational barriers to recruitment and retention; methodological complexities in fall outcome ascertainment; and context-specific constraints unique to the Indian LMIC setting—limited deprescribing guidelines, polypharmacy normalization, fragmented care coordination, and hierarchical decision-making. Global RCTs revealed substantial implementation challenges: low clinician adherence, short follow-up periods, restrictive eligibility excluding frail or cognitively impaired older adults, and resource-intensive interventions limiting scalability. Conclusions Deprescribing FRIDs in older adults is impeded by ethical, operational, methodological, and provider-patient challenges, necessitating multilevel strategies integrating training, shared decision-making, context-specific guidelines, and stakeholder engagement for scalable implementation.

The Journals of Gerontology Series A
Manipal Academy of Higher Education (IN), Malabar Institute of Medical Sciences (IN), Malabar Medical College Hospital and Research Centre (IN), Karolinska Institutet (SE), Indian Council of Medical Research (IN), Jawaharlal Institute of Post Graduate Medical Education and Research (IN), All India Institute of Medical Sciences (IN), Academy of Scientific and Innovative Research (IN)
Openalex Percentile: Top 14%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.